Related Experiment Videos
Tri-isobutylphosphate: a prenatal toxicity study in rats
S A Ruckman1, O P Green, A K Palmer
1Huntingdon Life Sciences Limited, Cambridgeshire, UK. ruckmans@ukorg.huntingdon.com
Toxicology Letters
|June 4, 1999
Summary
Tri-isobutylphosphate (CAS 126-71-6) showed maternal effects like salivation but no significant prenatal toxicity or teratogenicity in rats. Some developmental abnormalities occurred but were deemed coincidental.
Area of Science:
- Toxicology
- Reproductive Toxicology
- Developmental Toxicology
Background:
- Tri-isobutylphosphate (CAS 126-71-6) is an anti-foaming agent.
- Assessing its prenatal toxicity is crucial for safety evaluation.
Purpose of the Study:
- To evaluate the prenatal toxicity of tri-isobutylphosphate in pregnant rats.
- To determine potential embryotoxic or teratogenic effects.
Main Methods:
- Pregnant rats were administered daily oral doses (0, 100, 300, 1000 mg/kg) from day 6 to 15 of gestation.
- Maternal and fetal examinations were conducted on day 20 of pregnancy.
Main Results:
- Maternal effects included dose-related salivation and increased water consumption at the highest dose.
- No statistically significant impact on body weight gain was observed.
- No embryotoxic or teratogenic effects were detected in fetuses or litters.
- A cluster of 'hunched posture syndrome' was observed but considered coincidental.
Conclusions:
- Tri-isobutylphosphate did not demonstrate significant prenatal toxicity or teratogenicity in rats.
- The lowest observed adverse effect level (LOAEL) or no observed adverse effect level (NOAEL) for maternal effects requires further interpretation of salivation.
- Observed fetal abnormalities were likely coincidental and not treatment-related.